This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Why High Dividend, Low Volatility ETFs are Beating the Market
by Neena Mishra
These ETFs holds high quality, dividend paying stocks with low volatility
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
by Kanishka Das
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Is Legg Mason Low Volatility High Dividend ETF (LVHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for LVHD
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
Pharma Stock Roundup: J&J's Mixed Q1 Results, FDA Updates for GSK and AZN
by Kinjel Shah
J&J (JNJ) reports mixed first-quarter results and cuts full-year outlook. AstraZeneca (AZN) and Glaxo (GSK) provide FDA updates.
The Zacks Analyst Blog Highlights Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target
by Zacks Equity Research
Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target have been included in this Analyst Blog.
The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals
by Zacks Equity Research
Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.
Top Research Reports for Johnson & Johnson, Roche & Raytheon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Roche Holding AG (RHHBY), and Raytheon Technologies Corporation (RTX).
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
Company News for Apr 20, 2022
by Zacks Equity Research
Companies In The News Are: JNJ, CFG, CBSH, IRDM
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
by Zacks Equity Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
Musk v. Twitter Drama Continues to Play Out; JBHT Beats in Q1
by Mark Vickery
Even though Q1 earnings season is upon us, Wall Street remains somewhat captivated by the "Elon Musk Buying Twitter" story.
Stocks Slip on Monday as the Markets Brace for a Big Earnings Week
by Madeleine Johnson
Rising inflation, climbing Treasury yields, and mixed earnings results from the big banks were the main factors driving the market last week.
Housing Data Up for March; JNJ, LMT Mixed in Q1
by Mark Vickery
Market indexes are down to start the day, after rallying to near-flat during Monday's regular session.
Housing Market Remains Strong, Mortgage Rates To Rise
by Zacks Equity Research
Housing Market Remains Strong, Mortgage Rates To Rise.
J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View
by Zacks Equity Research
J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.
Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal
by Zacks Equity Research
Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.
Johnson & Johnson (JNJ) Tops Q1 Earnings Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.69% and 1.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?